Values as of: 2025-04-20
COMMON STOCK | Diagnostics & Research |
Last Closing
USD 148.08Change
0.00 (0.00)%Market Cap
USD 18.10BVolume
0.60MAnalyst Target
USD 56.20Verdict
Verdict
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Company Website : https://www.natera.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| IDXX | IDEXX Laboratories Inc |
N/A |
USD 33.82B |
| ICLR | ICON PLC |
N/A |
USD 14.94B |
| ILMN | Illumina Inc |
N/A |
USD 11.75B |
| MEDP | Medpace Holdings Inc |
N/A |
USD 8.68B |
| EXAS | EXACT Sciences Corporation |
N/A |
USD 8.47B |
| GH | Guardant Health Inc |
N/A |
USD 5.39B |
| RDNT | RadNet Inc |
N/A |
USD 3.68B |
| SHC | Sotera Health Co |
N/A |
USD 2.98B |
| WGS | GeneDx Holdings Corp. |
N/A |
USD 2.71B |
| VCYT | Veracyte Inc |
N/A |
USD 2.48B |
| Market Performance vs. Industry/Classification (Diagnostics & Research) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -6.46% | 73% | C | 61% | D- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -6.46% | 73% | C | 60% | D- | ||
| Trailing 12 Months | |||||||
| Capital Gain | 73.64% | 87% | B+ | 93% | A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 73.64% | 87% | B+ | 93% | A | ||
| Trailing 5 Years | |||||||
| Capital Gain | 322.00% | 100% | F | 94% | A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 322.00% | 100% | F | 93% | A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 42.19% | 83% | B | 87% | B+ | ||
| Dividend Return | 42.19% | 83% | B | 87% | B+ | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 80.31% | 40% | F | 23% | F | ||
| Risk Adjusted Return | 52.54% | 94% | A | 80% | B- | ||
| Market Capitalization | 18.10B | 98% | N/A | 96% | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total free cash flow in the most recent four quarters.
